Piramal Commits $40 Million On R&D For Cancer Molecules
This article was originally published in PharmAsia News
Executive Summary
India’s Piramal Healthcare said it plans to commit nearly $40 million during the current fiscal year to research and development for a pair of cancer molecules, one for suppressing tumors, the other for treating blood-cell cancer.